Fennec Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Hello, and thank you to JMP for inviting us here to the conference. We are Fennec Pharmaceuticals. My name is Robert Andrade. I'm the CFO of the company.
Our first slide will start with the customary safe harbor statements. This deck that you're going to be seeing here can also be found on our website under www.fennecpharma.com. And certainly, if there's any follow-up or questions, feel free to reach out to us.
Start with slide 3. This gives you a snapshot of the company. So, what is Fennec? Fennec, for the greater part of a decade nearly, has been focused on the development of PEDMARK. PEDMARK is for the prevention of cisplatinum-induced ototoxicity. Otherwise, the acronym known is CIO, or hearing loss in children. We have a proposed label with the FDA for the prevention of this CIO in all localized non-metastatic tumors.
To get to where we are today, we have successfully completed two randomized Phase 3 trials. Both have been published. The first one being
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
